10-Q: Oragenics Reports First Quarter 2024 Results, Focuses on Brain Injury Treatment

Oragenics, Inc. reported a net loss of $2.45 million for the first quarter of 2024, while shifting its focus to the development of ONP-002 for mild traumatic brain injury.

Summary

• Oragenics, Inc. is a development-stage company focused on nasal delivery pharmaceutical medications and vaccines.
• The company's lead product candidate is ONP-002 for the treatment of mild traumatic brain injury (mTBI or concussion).
• For the three months ended March 31, 2024, Oragenics reported a net loss of $2,450,833, or $0.70 per share, compared to a net loss of $2,844,837, or $1.41 per share, for the same period in 2023.
• Research and development expenses decreased to $663,414 from $1,672,576 in the prior year, primarily due to a shift in focus from COVID-19 vaccine and lantibiotics programs to ONP-002.
• General and administrative expenses increased to $1,796,689 from $1,249,263 in the prior year, due to increased accounting, investor relations, and personnel costs.
• The company's cash and cash equivalents decreased to $2,071,989 as of March 31, 2024, from $3,483,501 at the end of 2023.
• Oragenics believes its current working capital will only be sufficient to meet business objectives through the third quarter of 2024.
• The company is seeking additional funding through various means, including sublicensing, joint ventures, and public or private financings.
• A reverse stock split of one for sixty was implemented on January 20, 2023, and all historical share and per share amounts have been adjusted to reflect this split.
• On March 1, 2024, Oragenics closed an underwritten public offering of 1.4 million shares of common stock at $1.50 per share, raising gross proceeds of $2.1 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress with its lead asset, ONP-002, and has secured some funding, the financial situation is precarious, with limited cash runway and a delisting notice from the NYSE American. The need for additional funding and the legal dispute add to the uncertainty.

Positives

• The company has shifted its focus to ONP-002, a promising drug candidate for mild traumatic brain injury.
• The net loss for the first quarter of 2024 was lower than the same period in 2023.
• Research and development expenses have decreased due to the strategic shift in focus.
• ONP-002 has completed a Phase 1 clinical trial, demonstrating safety and tolerability.
• The company has secured $2.1 million in gross proceeds through a public offering.
• Preclinical studies of ONP-002 have shown positive behavioral outcomes in animals with improved memory and sensory-motor performance.

Negatives

• The company reported a net loss of $2.45 million for the first quarter of 2024.
• General and administrative expenses increased significantly.
• Cash and cash equivalents have decreased to $2.07 million.
• The company's current cash resources are only expected to last through the third quarter of 2024.
• Oragenics received a notice of non-compliance from the NYSE American due to insufficient shareholder equity.
• The company has paused research and development activities related to its vaccine product candidate and lantibiotics program due to limited resources.

Risks

• The company has a history of recurring losses and negative cash flows from operations.
• There is substantial doubt about the company's ability to continue as a going concern beyond the third quarter of 2024.
• The company's ability to continue operations depends on obtaining additional financing or achieving profitable operations.
• Failure to obtain additional funding could lead to curtailment of development programs and other opportunities.
• The company is subject to the risk of delisting from the NYSE American due to non-compliance with listing standards.
• The company is involved in a legal dispute with Ladenburg Thalmann, which could have a material adverse impact.
• The company's future success is heavily reliant on the successful development and commercialization of ONP-002.
• The company has paused research and development of its vaccine and lantibiotics programs, which could limit future growth opportunities.

Future Outlook

The company plans to advance the development of ONP-002, including initiating Phase 2 clinical trials, and is seeking additional funding to support its operations and research programs. The company is also evaluating opportunities for its other assets.

Management Comments

• The company is focused on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury.
• The company believes its working capital at March 31, 2024 will be sufficient to meet the business objectives as presently structured only through the third quarter of 2024.
• The company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings.
• The company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE Americans requirements.

Industry Context

The global market for concussion treatment is estimated to reach $8.9 billion by 2027, indicating a significant opportunity for Oragenics' ONP-002. The company's focus on a novel intranasal delivery method aligns with the industry's trend towards more efficient and targeted drug delivery systems.

Comparison to Industry Standards

• Oragenics' shift to focus on ONP-002 for mTBI aligns with the growing interest in neuroprotective therapies, similar to companies like Biohaven Pharmaceuticals (now part of Pfizer) which developed Nurtec ODT for migraine.
• The company's intranasal delivery approach is similar to that of companies like Impel NeuroPharma, which uses a nasal delivery system for acute migraine treatment, but Oragenics is targeting a different therapeutic area.
• The company's financial situation, with limited cash resources and a need for additional funding, is not uncommon for development-stage biotech companies, many of which rely on capital raises and partnerships to advance their pipelines.
• The company's research and development expenses are lower than those of larger pharmaceutical companies, reflecting its current stage of development and focus on a single lead asset.
• The company's net loss per share of $0.70 is not directly comparable to companies with approved products and revenue streams, but it is a key metric for investors to track the company's progress.

Legal Proceedings

• The company is involved in a legal dispute with Ladenburg Thalmann regarding a fee related to the Odyssey NeuroPharma asset purchase.
• The company initiated a confidential action for arbitration against Ladenburg with the Financial Industry Regulatory Authority (FINRA) on March 12, 2024.
• Ladenburg filed a Complaint in federal court in the Southern District of Florida on April 17, 2024, and also filed motion for a temporary restraining order (TRO) and preliminary injunction seeking to move the venue from FINRA to the federal court in Miami-Dade County.
• On May 3, 2024 the Magistrate Judge assigned to the case issued a Report and Recommendation denying the motion.
• On May 9, 2024, the Company filed a motion to dismiss in the federal court action to ensure that the FINRA action continues.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential delisting from the NYSE American.
• Employees may be affected by cost-saving initiatives, including potential staff reductions.
• Customers and partners may be impacted by the company's financial instability and potential delays in product development.
• Creditors may be concerned about the company's ability to repay debts given its limited cash resources.

Next Steps

• The company plans to initiate Phase 2 clinical trials for ONP-002 in Australia in the second or third quarter of 2024.
• The company plans to apply for an Investigational New Drug application with the FDA and conduct a Phase 2 trial in the United States.
• The company must submit a plan of compliance to the NYSE American by May 18, 2024.
• The company will continue to seek additional funding through various means.

Key Dates

Keywords

ONP-002, mild traumatic brain injury, concussion, nasal delivery, clinical trials, pharmaceutical, biotechnology, research and development, financing, NYSE American